Financial Commitments & Contingencies and Key License Agreements - Additional Information (Details) - USD ($)		1 Months Ended		12 Months Ended
	Jan. 01, 2022	Dec. 31, 2020	Apr. 30, 2018	Dec. 31, 2022	Dec. 31, 2021
Long-term Purchase Commitment [Line Items]
Right-of-use assets in exchange for lease liabilities				$ 400,000	$ 1,800,000
Facility and equipment under lease				1,694,000	2,505,000
Accounts payable and other accrued liabilities				38,105,000	41,258,000
Accrued payroll and benefits				4,580,000	11,971,000
Deferred compensation liability, current and noncurrent				4,500,000	11,200,000
Tom Riga
Long-term Purchase Commitment [Line Items]
Accrued payroll and benefits					3,100,000
Hanmi | ROLVEDON, Co-Development and Commercialization Agreement
Long-term Purchase Commitment [Line Items]
Reduction in accrued liabilities	$ 11,200,000
Royalty expense				400,000
Inventory purchases				9,000,000
Accounts payable and other accrued liabilities				9,800,000
Hanmi | Eflapegrastim: Co-Development and Commercialization Agreement with Hanmi
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones			$ 10,000,000
Hanmi | Poziotinib: In-License Agreement with Hanmi and Exclusive Patent and Technology License Agreement with MD Anderson
Long-term Purchase Commitment [Line Items]
Achievement of regulatory milestones potential payments	18,000,000
Supplemental royalty milestone limit	$ 15,000,000
MD Anderson
Long-term Purchase Commitment [Line Items]
Achievement of regulatory milestones potential payments			6,000,000
Payment of upfront fee			500,000
Potential payments based on achievement of sales milestones			$ 24,000,000
Therapyx | In-License Agreement with Therapyx
Long-term Purchase Commitment [Line Items]
Asset purchase agreement, upfront payment		$ 800,000
Potential payments based on worldwide annual net sales		167,500,000
Therapyx | In-License Agreement with Therapyx | Acceptance of certain transferred materials
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones		2,200,000
Therapyx | In-License Agreement with Therapyx | First approved IL-12 product
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones		30,000,000
Therapyx | In-License Agreement with Therapyx | Each new indication approved for each product in the U.S., Europe, or Japan
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones		$ 2,500,000
Office and research facilities
Long-term Purchase Commitment [Line Items]
Facility and equipment under lease				1,400,000	2,100,000
Office equipment
Long-term Purchase Commitment [Line Items]
Facility and equipment under lease				$ 300,000	$ 400,000
Minimum
Long-term Purchase Commitment [Line Items]
Remaining term				2 years
Maximum
Long-term Purchase Commitment [Line Items]
Remaining term				4 years